Amylyx Completes Enrollment for Key Phase 3 LUCIDITY Trial and Phase 1 LUMINA Cohort 2
AMLX has more than doubled off its 52-week low of $3.11.
Summary
Amylyx Pharmaceuticals announced the completion of enrollment for its Phase 3 LUCIDITY trial for avexitide and Phase 1 LUMINA trial Cohort 2, advancing its late-stage and early-stage clinical programs.
Key Events · Product Development and Regulatory · AMLX
-
Phase 3 LUCIDITY Trial Enrollment Complete
Enrollment for the pivotal Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia (PBH) has been completed, with topline data now expected in Q3 2026 and a potential commercial launch in 2027 if approved.
-
Phase 1 LUMINA Trial Cohort 2 Enrollment Complete
Enrollment for Cohort 2 of the Phase 1 LUMINA trial for AMX0114 in ALS has been completed. Early data from Cohort 1 showed AMX0114 was generally well-tolerated with no treatment-related serious adverse events.
-
Updated Pipeline Progress
The corporate presentation also highlighted positive Phase 2 HELIOS data for AMX0035 in Wolfram syndrome and the nomination of AMX0318 as a preclinical development candidate for PBH and other rare diseases.
-
Extended Cash Runway
The company reported a cash runway expected into 2028, with $317 million in cash, cash equivalents, and short-term investments as of December 31, 2025.
Analysis · AMLX · Life Sciences
Amylyx Pharmaceuticals announced significant progress across its clinical pipeline, notably completing enrollment for its pivotal Phase 3 LUCIDITY trial for avexitide in post-bariatric hypoglycemia (PBH). This milestone de-risks the program and sets the stage for topline data in Q3 2026, with a potential commercial launch in 2027. Additionally, the company completed enrollment for Cohort 2 of its Phase 1 LUMINA trial for AMX0114 in ALS, further advancing its neurodegenerative disease pipeline. These updates, coupled with a strong cash runway into 2028, indicate solid operational execution and progress towards key clinical readouts.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1594 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AMLX was trading at $14.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $3.11 to $17.49. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.